Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Dermatol Clin. 2017 Jan;35(1):73–84. doi: 10.1016/j.det.2016.07.003

Fig. 7.

Fig. 7

Model of cyclosporine effects on cutaneous SCC. It is possible that CSA acts through the IL-22 axis to drive aggressive behavior by SCC. CSA treatment promotes SCC growth, invasive capacity, and IL-22 receptor expression. The authors have previously shown that IL-22 treatment promotes SCC growth. In addition to decreased tumor immune surveillance, CSA treatment enhances Treg numbers and IL-22 production by CD4+ and CD8+ T cells. Therefore, higher IL-22 receptor expression on SCC tumor cells and increased levels of IL-22 cytokine produced by CD8+ and CD4+ T cells may contribute to tumor growth.